Evidence map›Paper›PMID 38069220›Full record

ArticleInternational journal of molecular sciences2023

Pharmacological Inhibition of PIP4K2 Potentiates Venetoclax-Induced Apoptosis in Acute Myeloid Leukemia.

Keli Lima, Maria Fernanda Lopes Carvalho, Diego Antonio Pereira-Martins, Frederico Lisboa Nogueira, Lívia Bassani Lins de Miranda, Mariane Cristina do Nascimento, Rita de Cássia Cavaglieri, Jan Jacob Schuringa, João Agostinho Machado-Neto, Eduardo Magalhães Rego

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. In Vitro Anti-Breast Cancer Effects ofInternational journal of molecular sciences · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Keli LimaLaboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo CEP 13566-590, Brazil.ORCID 0000-0002-5498-7539
Maria Fernanda Lopes CarvalhoDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo CEP 13566-590, Brazil.ORCID 0000-0002-9712-6050
Diego Antonio Pereira-MartinsLaboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo CEP 13566-590, Brazil.ORCID 0000-0002-3302-4311
Frederico Lisboa NogueiraLaboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo CEP 13566-590, Brazil.ORCID 0000-0003-1337-7635
Lívia Bassani Lins de MirandaDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo CEP 13566-590, Brazil.
Mariane Cristina do NascimentoLaboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo CEP 13566-590, Brazil.
Rita de Cássia CavaglieriDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo CEP 13566-590, Brazil.
Jan Jacob SchuringaDepartment of Experimental Hematology, University of Groningen, 9718 BG Groningen, The Netherlands.
João Agostinho Machado-NetoDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo CEP 13566-590, Brazil.ORCID 0000-0002-2937-8109
Eduardo Magalhães RegoLaboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo CEP 13566-590, Brazil.ORCID 0000-0003-1567-4086
Universidade de São Paulo · BRUniversity of Groningen · NL

Funding

Coordenação de Aperfeicoamento de Pessoal de Nível Superior Finance Code 001São Paulo Research Foundation #2017/23117-1São Paulo Research Foundation #2020/12842-0São Paulo Research Foundation #2021/11606-3São Paulo Research Foundation #2022/03316-8São Paulo Research Foundation #2022/14505-6
6 · The paper itself

Abstract

Phosphatidylinositol-5-phosphate 4-kinase type 2 (PIP4K2) protein family members (PIP4K2A, PIP4K2B, and PIP4K2C) participate in the generation of PIP

Indexed as

Antineoplastic AgentsLeukemia, Myeloid, AcuteApoptosisBridged Bicyclo Compounds, HeterocyclicCell Line, TumorHumansPhosphotransferases (Alcohol Group Acceptor)Proto-Oncogene Proteins c-bcl-2SulfonamidesAntineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicPhosphotransferases (Alcohol Group Acceptor)PIP4K2A protein, humanProto-Oncogene Proteins c-bcl-2Sulfonamidesvenetoclaxacute myeloid leukemiaphosphatidylinositol-5-phosphate 4-kinase type 2THZ-P1-2venetoclax

Identifiers

PMID38069220
PMCPMC10706459
OpenAlexW4389145735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.